5-Hydroxy-1-methyl-3-methylsulfanylpyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 5-Hydroxy-1-methyl-3-methylsulfanylpyrrolidin-2-one
• 英文别名: 5-hydroxy-1-methyl-3-methylsulfanylpyrrolidin-2-one
• 化学式: C₆H₁₁NO₂S
• 分子量: 161.225
• InChiKey: HTRPTRUAAIQZEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  65.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  环氧乙烷 、 5-Hydroxy-1-methyl-3-methylsulfanylpyrrolidin-2-one 在 potassium hydroxide 作用下， 生成
  参考文献：
  名称：

  CN117185973

  摘要：

  公开号：

文献信息

• [EN] MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT INHIBITEURS DE MCL-1 ET PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2022115451A1

  公开（公告）日：2022-06-02

  Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on a tumor or other cancer cell. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.

  本文披露了抗CD48抗体药物结合物。该抗CD48抗体药物结合物包括Mcl-1抑制剂药物部分和抗CD48抗体或其抗原结合片段，其结合抗原靶点，例如在肿瘤或其他癌细胞上表达的抗原。本文进一步涉及使用所提供的抗体药物结合物治疗癌症的方法和组合物。还披露了包含Mcl-1抑制剂药物部分的连接体-药物结合物和制备方法。
• [EN] BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT INHIBITEURS DE BCL-XL ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NOVARTIS AG

  公开号：WO2022115477A1

  公开（公告）日：2022-06-02

  Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody- drug conjugates comprise a Bcl-xL inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody- drug conjugates provided herein. Linker-drug conjugates comprising Bcl-xL inhibitor drug moiety and methods of making same are also disclosed.

  本文揭示了结合人类肿瘤靶点的抗体药物偶联物。这些抗体药物偶联物包括Bcl-xL抑制剂药物部分。本文还涉及使用本文提供的抗体药物偶联物治疗癌症的方法和组合物。本文还揭示了包含Bcl-xL抑制剂药物部分的连接剂-药物偶联物及其制备方法。
• PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND
  申请人：XDCExplorer (Shanghai) Co., Ltd.

  公开号：EP3650464A1

  公开（公告）日：2020-05-13

  Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by formula (1), and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.         Cap-AA1-AA2-XX3-Asn-AA5-AA6-AA7-Leu-AA9-AA10-P     (1)

  本发明公开了一种多肽化合物及其应用，以及一种含有该多肽化合物的组合物。本发明提供了一种由式（1）表示的多肽化合物及其药学上可接受的盐、同系物、溶液、晶型或原药。该化合物对 Kiss1R 具有良好的稳定性和活性。 Cap-AA1-AA2-XX3-Asn-AA5-AA6-AA7-Leu-AA9-AA10-P (1)
• ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF
  申请人：Mabplex International, Ltd.

  公开号：EP3797796A1

  公开（公告）日：2021-03-31

  Provided is an antibody-drug conjugate (ADC) using one or more cysteine or derivatives thereof as linkers to couple one or more drugs at the limited binding sites of an antibody, making it possible to produce an ADC product with high drug payload, or to choose a drug with less toxicity, thereby obtaining an ADC product with wide therapeutic window. In addition, since a plurality of drugs may be coupled to one binding site, the ADC products obtained by the method of the present disclosure have better uniformity in the case of same DAR value. Moreover, the amount of antibody required for production may be greatly reduced, thereby lowering the cost. Compared with the antibody-drug conjugates coupled only one drug, the antibody-drug conjugates produced by the method of the present disclosure have the same inhibition or killing effect on tumor cells while using fewer drugs for coupling to the same site.

  本发明提供了一种抗体-药物共轭物（ADC），使用一种或多种半胱氨酸或其衍生物作为连接体，在抗体的有限结合位点上偶联一种或多种药物，从而可以生产出药物载量高的 ADC 产品，或选择毒性低的药物，从而获得治疗窗口宽的 ADC 产品。此外，由于一个结合位点可偶联多种药物，因此在 DAR 值相同的情况下，通过本公开的方法获得的 ADC 产品具有更好的一致性。此外，还可大大减少生产所需的抗体量，从而降低成本。与只与一种药物偶联的抗体-药物共轭物相比，本公开方法制备的抗体-药物共轭物对肿瘤细胞具有相同的抑制或杀伤作用，而与同一位点偶联的药物用量更少。
• PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP2459228B1

  公开（公告）日：2020-03-04